TY - JOUR
T1 - Hodgkin lymphoma in very young children
T2 - Clinical characteristics and outcome of treatment
AU - Belgaumi, Asim
AU - Al-Kofide, Amani
AU - Joseph, Nicey
AU - Jamil-Malik, Rubina
AU - Khafaga, Yasser
AU - Sabbah, Rajeh
PY - 2008/5
Y1 - 2008/5
N2 - In developed nations, Hodgkin lymphoma (HL) is rare in <-year olds and represent a minority in developing countries. Little is reported about the biology and behavior of these very young patients compared with older children. 18.75% of our pediatric HL patients (0-14 years) were <5 years at diagnosis. This group had more boys, similar incidence of B-symptoms and stage distribution, less mediastinal involvement and bulky disease, and more mixed cellularity subtype than older children. Treatment included chemotherapy (CT; n = 55), combined modality therapy (CMT; n = 12) and XRT only (n = 2). Ten-year EFS and OS was 81.5% and 90.4%, respectively, versus 75.5% and 90.5% for older children (p > 0.5). A trend toward better survival was seen with CMT, using very LD-XRT, than with CT (OS 100% vs. 86.4%[p = 0.3]; EFS 90.9% vs. 81.0%[p = 0.4]). Although CT could be effective in a subset of LR patients, LD-XRT may be needed to effectively treat most of these patients. This dose reduction may reduce XRT-related toxicity, which can be significant in very young children.
AB - In developed nations, Hodgkin lymphoma (HL) is rare in <-year olds and represent a minority in developing countries. Little is reported about the biology and behavior of these very young patients compared with older children. 18.75% of our pediatric HL patients (0-14 years) were <5 years at diagnosis. This group had more boys, similar incidence of B-symptoms and stage distribution, less mediastinal involvement and bulky disease, and more mixed cellularity subtype than older children. Treatment included chemotherapy (CT; n = 55), combined modality therapy (CMT; n = 12) and XRT only (n = 2). Ten-year EFS and OS was 81.5% and 90.4%, respectively, versus 75.5% and 90.5% for older children (p > 0.5). A trend toward better survival was seen with CMT, using very LD-XRT, than with CT (OS 100% vs. 86.4%[p = 0.3]; EFS 90.9% vs. 81.0%[p = 0.4]). Although CT could be effective in a subset of LR patients, LD-XRT may be needed to effectively treat most of these patients. This dose reduction may reduce XRT-related toxicity, which can be significant in very young children.
KW - Chemotherapy
KW - Childhood
KW - Hodgkin lymphoma
KW - Toxicity
UR - http://www.scopus.com/inward/record.url?scp=46749114044&partnerID=8YFLogxK
U2 - 10.1080/10428190801947492
DO - 10.1080/10428190801947492
M3 - Article
C2 - 18464110
AN - SCOPUS:46749114044
SN - 1042-8194
VL - 49
SP - 910
EP - 916
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 5
ER -
